perpetuity. It is made available under a CC-BY 4.0 International license .

# MDPI

## Article Use of high-plex data reveals novel insights into the tumour microenvironment of clear cell renal cell carcinoma

Raffaele De Filippis <sup>1,†</sup><sup>(D)</sup>, Georg Wölflein <sup>2,†</sup><sup>(D)</sup>, In Hwa Um <sup>1</sup>, Peter D Caie <sup>3</sup>, Sarah Warren <sup>4</sup>, Andrew White <sup>4</sup>, Elizabeth Suen <sup>1</sup>, Emily To <sup>1</sup>, Ognjen Arandjelović <sup>2,\*</sup><sup>(D)</sup> and David J Harrison <sup>1,\*</sup><sup>(D)</sup>

- <sup>1</sup> School of Medicine, University of St Andrews, UK
- <sup>2</sup> School of Computer Science, University of St Andrews, UK
- <sup>3</sup> Indica Labs
- <sup>4</sup> NanoString Technologies
- \* Correspondence: david.harrison@st-andrews.ac.uk / ognjen.arandjelovic@gmail.com
- + First co-authors

Simple Summary: Cancer is a complex ensemble of morphological and molecular features whose role is still unclear. Moreover, their role may change in different areas of the same tumour. Artificial intelligence (AI) allows pathologists to go beyond human perception and bias, and may help better understand how these features influence disease progression. Furthermore, by capturing variation intrinsic to the tumour, AI may improve the accuracy of current prognostic tools, such as Leibovich Score (LS), in predicting patient outcome and response to therapy. For these reasons, we studied in clear cell renal cell carcinoma (ccRCC) tissue, in which molecular features and their coexpression in the same cell were quantified and mapped using AI-based image analysis software. We demonstrated a novel approach for investigating ccRCC and revealed new potential biomarkers of prognosis which may also be able to direct patients towards the most appropriate personalised therapy.

Abstract: Although Immune Checkpoint Inhibitors (ICIs) have significantly improved Clear Cell 11 Renal Cell Carcinoma (ccRCC) prognosis, about one third of patients experience recurrence. Cur-12 rent prognostic algorithms like the Leibovich Score (LS) rely on morphological features manually 13 assessed by pathologists, and are therefore subject to bias. Moreover, these tools do not consider 14 the heterogeneous molecular milieu present in the Tumour Microenvironment (TME), which may 15 have prognostic value. We systematically developed a semi-automated method to investigate 62 16 markers and their combinations in 150 primary ccRCCs using multiplex Immunofluorescence (mIF), 17 NanoString GeoMx® Digital Spatial Profiling (DSP) and Artificial Intelligence (AI)-assisted image 18 analysis in order to find novel prognostic signatures and investigate their spatial relationship. We 19 found that coexpression of Cancer Stem Cell (CSC) and Epithelial-to-Mesenchymal Transition (EMT) 20 markers such as OCT4 and ZEB1 are indicative of poor outcome. OCT4 and the immune markers 21 CD8, CD34 and CD163 significantly stratified patients at intermediate LS. Furthermore, augmenting 22 the LS with OCT4 and CD34 improved patient stratification by outcome. Our results support the 23 hypothesis that combining molecular markers has prognostic value and can be integrated with 24 morphological features to improve risk stratification and personalised therapy. To conclude, GeoMx<sup>®</sup> 25 DSP and AI image analysis are complementary tools providing high multiplexing capability required 26 to investigate the TME of ccRCC, while reducing observer bias. 27

**Keywords:** multiplex; immunofluorescence; nanostring; image analysis; pathology; kidney; spatial analysis 28

#### 1. Introduction

Attri-bution (CC BY) license (https:// NOTE: This preprint reports the discrete that in the present to any the discrete that it to any the discrete the discrete that it to any the discrete the discrete the discrete that it to any the discrete th

Citation: De Filippis, R.; Wölflein, G.; Um, I.H.; Caie, P.; Warren, S.; White, A.; Suen, E.; To, E.; Arandjelović, O.; Harrison, D.J. Use of high-plex data reveals novel insights into the tumour microenvironment of clear cell renal cell carcinoma. *Cancers* **2022**, *1*, 0. https://doi.org/

Received: Accepted: Published:

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Copyright: © 2022 by the authors. Submitted to *Cancers* for possible open access publication under the terms and conditions of the Creative Commons Attri-bution (CC BY) license (https:// NOTE: This preprint rep creativecommons.org/ licenses/by/ 4.0/).

perpetuity. It is made available under a CC-BY 4.0 International license .

Version October 13, 2022 submitted to Cancers

2 of 21

nephrectomy, although 30% of patients experience recurrence [2]. Even though tremendous progress has been made in systemic therapy with the advent of immune checkpoint inhibitors (ICIs), around one third of patients present with metastasis, and their 5-year survival drops to 12% [3,4].

The current clinical gold standard prognostic tools are TNM staging and International Society of Urological Pathology (ISUP) nuclear grading, obtained through Haematoxylin & Eosin (H&E) staining of resected tissue sections. The former considers the tumour size (pT), lymph node involvement (pN), and the presence of distant metastasis (pM); the latter takes into account nucleolar prominence and morphology, as well as the presence of rhabdoid and sarcomatoid features [5,6].

Several prognostic algorithms have been built to assign prognostic scores to patients and predict the risk of advanced disease. For instance, the widely used Leibovich score (LS) predicts the risk of recurrence after surgery by considering pT, pN, tumour size, nuclear grade, and the presence of necrosis (table 1). However, LS only considers tumour morphological features, which are subjectively assessed by pathologists, while there is a lack of general consensus about molecular features. For these reasons, current prognostic tools, such as LS, are subject to inter-observer bias are unable to accurately predict patient outcome and response to therapy [6,7].

Other factors may influence tumour progression: ccRCC is characterised by a highly 52 heterogeneous Tumour Microenvironment (TME), in which hypoxia, blood vessels, stromal, 53 and immune cells play a crucial role for cancer progression. For example, variations in 54 immune escape mechanisms, such as PD-1/PD-L1 interaction, which are at the base of 55 some ICIs, are responsible for drug resistance [8]. Therefore, assessing molecular marker 56 expression such as PD-1 and PD-L1 could predict the response to therapy, and distinguish 57 patients who would benefit from treatment from those who would potentially experience 58 adverse effects. After exposure to chronic inflammation, cytotoxic T cells express high 59 levels of co-inhibitory receptors, including PD-1, LAG-3, TIM-3, and CTLA-4. This results 60 in T cell loss of function, and tumour adaptation to the immune response, favouring disease 61 progression. The main exhausted T cell molecular signature is represented by coexpression 62 of CD8 along with PD-1 and TIM-3 and was associated to poor prognosis in ccRCC [9]. 63

Moreover, recent evidence supports the hypothesis that high PD-1/PD-L1 expression 64 and increased regulatory T cell infiltration promote epithelial-mesenchymal transition 65 (EMT), a process in which epithelial cells acquire a mesenchymal phenotype [10]. These signals lead to cytoskeleton reorganisation and cell motility, which are associated with inva-67 siveness and metastatic potential in cancer [11]. The hallmark of EMT is the upregulation of N-cadherin followed by the downregulation of E-cadherin [12]. Although the origin 69 of EMT is still unclear, evidence suggests that the transforming growth factor  $\beta$  (TGF- $\beta$ ) 70 induces EMT by activating transcription factors including vimentin, snail, and zinc finger 71 E-box binding homeobox 1 (ZEB1), which suppress epithelial cell proliferation [13–15]. 72 In particular, vimentin is involved in the cytoskeleton reorganisation [16], whereas ZEB1 73 represses E-cadherin expression and activates N-cadherin and vimentin expression [17]. 74

Interestingly, it has recently been shown that cancer stem cells (CSCs) require a hybrid epithelial/mesenchymal phenotype in order to initiate cancer progression [18]. These dedifferentiated tumour cells hold self-renewal potential and cell motility which contribute to tumour aggressiveness and poor prognosis [19].

However, no standard CSC markers exist for ccRCC due to the high heterogeneity of its TME, although some have shown a prognostic potential. For instance, CD44 is involved in the regulation of stem cell features via the Wnt/b-catenin signalling pathway, suggesting that this marker could contribute to EMT [20]. Moreover, CD44 was associated with poor 5-year survival, high nuclear grade and recurrence in ccRCC [21]. To note, in vitro studies using RCC cell lines observed that CD44 was upregulated in the presence of tumour-associated macrophages (TAMs) [22].

OCT4 has also been shown to be responsible for stemness, EMT, tumorigenesis, and cell survival mechanisms [23]. In ccRCC, OCT4a, either alone or in combination with

perpetuity. It is made available under a CC-BY 4.0 International license .

Version October 13, 2022 submitted to Cancers

3 of 21

NANOG, was associated with stemness and poor prognosis [24]. CSCs have also been shown to bind to CTLA-4 receptor causing CTLA-4 upregulation. These evidences suggest that CSCs may also be involved in immune evasion and T cell exhaustion [25,26], showing how all the mechanisms described above are strictly connected to each other symbiotically modulating the TME.

Understanding the high ccRCC intra-tumour heterogeneity (ITH) is crucial for patient stratification in order to achieve personalised therapy. Therefore, a better investigation of ccRCC TME is necessary, and novel approaches, such as multiplex immunofluorescence (mIF) and spatial profiling *in situ* can play a crucial role. Artificial intelligence (AI) and machine learning (ML) applied to image analysis have revolutionised digital pathology, allowing more precise quantification, generating more data, and overcoming inter-observer variability [27].

We systematically developed a semi-automated method to assess 62 and 158 features 100 in Tissue Microarray (TMA) and whole slide tissue sections, respectively. Subsequently, we 101 assessed their relationship and their correlation with outcome using ML-based statistical 102 tools (Figure 1). This approach may facilitate the discovery of novel molecular signatures 103 able to predict outcome and in order to choose the best therapeutic strategy and avoid 104 ineffective and potentially harmful drug administration. 105

Table 1. Leibovich score

Tumour status	Score
pT1a	0
pT1b	2
pT2	3
pT3a	4
pT3b	4
pT3c	4
pT4	4
Lymph node involvement	Score
pNx	0
pN0	0
pN1	0
pN2	0
Tumour size	Score
<10cm	0
$\geq 10$ cm	1
Nuclear grade	Score
1	0
2	0
3	1
4	3
Necrosis	Score
Absent	0
Present	1
Risk group	Score
Low	0-2
Intermediate	3-5
High	$\geq 6$

## 2. Materials and Methods

#### 2.1. Study population

Tissues samples resected from 150 patients who were diagnosed with ccRCC and treated by radical nephrectomy between the years 1983 and 2018 were extracted from the pathology archive in Edinburgh and verified by an experienced pathologist. Specimens

Version October 13, 2022 submitted to Cancers

4 of 21

130

138

155

156

were collected prior to therapy administration: none of these patients had therapy before 111 surgery, and none received immune blockade therapy. 112

The analysed cohort consisted of 60 females and 86 males: Gender of 4 patients was 113 not available. The average age was 64 years and mean follow-up was 60 months. 106 114 patients (70%) were reported to be deceased, of which 75 (50%) experienced cancer-related 115 death (CRD). 5-year survival rate was 66%. 46 patients (30%) experienced metastasis at the 116 time of diagnosis and for them, overall survival (OS) rate was 46% and 5-year survival rate 117 was 58%. 118

A total of 124 patients had LS data, although no necrosis data were available. The 110 majority of patients presented stage 3 and intermediate LS risk, while nuclear grades 2 120 and 3 were the most common. Finally, a total of 18 patients (14.5%) presented lymph node 121 involvement (pN=1) and 35 patients (28.2%) presented distant metastasis. More detailed 122 information is available in supplementary table A. 123

From each primary sample, 3 tissue punches were randomly collected and stored in 124 11 tissue microarray (TMA) blocks. Clinical information was retrieved from the patients' 125 medical records, including age, sex, cancer-specific survival, time after initial surgery, TNM 126 stage and nuclear grade. The tissue samples, clinical data, and ethical approval for this 127 retrospective study were issued by the Research Tissue Bank and the SAHSC Bio Resource 128 on behalf of NHS Lothian (15/ES/0094). 129

#### 2.2. Antibody optimisation

Antibodies were first optimised separately on optimisation TMAs, consisting of sev-131 eral different normal and cancer tissues (RCC, breast, gastric, colon, prostate, tonsil, spleen 132 etc) and then on RCC TMAs from the study cohort. All antibodies were optimised first in 133 brightfield immunoperoxidase and then for immunofluorescence (IF). For tumour cell seg-134 mentation in immunofluorescence (IF), a combination of CA9 and pan-Cadherin antibodies 135 was applied. The list of antibodies used, along with the dilution used is shown in Table B1 136 in the appendix. 137

### 2.3. Multiplex immunofluorescence

Formalin-fixed, paraffin-embedded (FFPE) tissues were first de-waxed in xylene 139 and then re-hydrated through descending concentrations of ethanol. In order to expose 140 epitopes, heat-mediated antigen retrieval was performed in an electric pressure cooker 141 using TRIS-EDTA buffer (pH 9). Subsequently, slides were treated with 3% hydrogen 142 peroxide to block endogenous peroxidase activity, and with protein block (Agilent, X090930-143 2), in order to prevent non-specific staining. Slides were then incubated with primary 144 antibodies for either one hour or 30 minutes at room temperature, or overnight at 4°C. 145 After primary incubation, tissues were then incubated with secondary HRP-conjugated 146 or biotin-conjugated antibodies for 30 minutes at room temperature. Slides were treated 147 either with cyanine 3, cyanine 5, fluorescein, using Tyramide Signal Amplification (TSA) 148 system, or Alexa Fluor 750 (ThermoFisher, S21384), diluted in amplification diluent (Perkin 149 Elmer, FP1498) and antibody diluent (Agilent, S080983-2), respectively. Hoechst 33342 150 (ThermoFisher, H3570), diluted in PBS, was used for nuclear counterstaining. Finally, slides 151 were dehydrated in ethanol, air-dried and mounted using Prolong anti-fade mounting 152 medium (ThermoFisher, P36930). The full list of primary antibodies used is shown in 153 table B1 of the appendix. 154

## 2.4. GeoMx<sup>®</sup> Digital spatial profiling

#### 2.4.1. Sample preparation

Slides were prepared according to the digital spatial profiling (DSP) FFPE Protein Man-157 ual (MAN-10100-05). FFPE slides were baked for one hour at 60°C before being treated with CitroSolv (Fisher, 22-143-975) and descending concentrations of ethanol. Antigen retrieval 159 in Citrate buffer (pH 6) was performed in a pressure cooker and slides were then washed 160 in TBS-T, blocked with Buffer W (Iba 2-1003-100) and incubated overnight at 4°C with 62 161

Version October 13, 2022 submitted to Cancers



**Figure 1.** Heatmap showing positive (red), negative (blue) or no (white) correlation among markers assessed in the Whole Slides (WSs) after unsupervised clustering. 156 features were assessed, including morphological features, molecular marker combination in tumour and immune cells, as well as spatial analysis data. Only correlations with p < 0.05 after Chow-Denning correction are shown. No negative correlations were reported.

medRxiv preprint doi: https://doi.org/10.1101/2022.10.13.22281035; this version posted October 13, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license

Version October 13, 2022 submitted to Cancers

UV-cleavable Oligonucleotide-conjugated antibodies for DSP and Fluorescent-labelled antibodies for visualisation (Pan Cadherin - Alexa Fluor 488, Syto83 - Alexa Fluor 532, CD3e 163 Alexa Fluor 594, CD163 - Alexa Fluor 647). The Oligonucleotide-conjugated antibodies 164 consisted of five panels (immune cell profiling, immune activation status, immune cell 165 typing, tumour markers and drug targets), and are shown in table B2 of the appendix.

## 2.4.2. DSP and nCounter<sup>®</sup> Readout

After incubation, the slides were loaded into the GeoMx<sup>®</sup> digital spatial profiler, where 168 the tissues were scanned and digital images were generated for region of interest (ROI) 169 selection. Each TMA core corresponded to a ROI. Subsequently, ROIs were illuminated 170 with UV light and oligo tags were released into the aqueous layer just above the slide, 171 which was aspirated through a micro capillary tube and stored in a single well of a 96-well 172 plate. This process was repeated for each ROI. An average of 120 ROIs per slide were 173 collected. nCounter Readout was processed according to the GeoMx DSP Readout Manual 174 (MAN-10091-09), and as previously described [28,29]. 175

#### 2.4.3. DSP Quality control and normalisation

Quality control was based on marker density and was automatically performed by the nSolver® software by NanoString Technology. Data normalisation was based on mouse IgG1 and IgG2 antibodies included in the antibody mix, which were considered as negative controls. Raw data were converted to a log<sub>2</sub> scale. For each ROI, corresponding to the TMA core, the mean of the IgG1 and IgG2 was used to calculate the signal-to-noise ratio (SNR) as

$$SNR = X - \frac{IgG_1 + IgG_2}{2} \tag{1}$$

where X is the count of a single marker in a single ROI. Since NanoString suggests that 177 SNR should be  $> \log_2(3)$ , values greater than 1.5 were considered a positive signal. In 178 order to keep the data intact, values below 1.5 were clamped to 1.5. 179

#### 2.5. Image analysis

TMA images were analysed using Definiens<sup>®</sup> Tissue Studio. Around 10% of images 181 were used for training and several training rounds were performed to reach optimal results. For each TMA core, tumour-stroma segmentation was performed and only the tumour 183 areas were considered since most cores consisted of over 90% tumour (Figures 2A and 2B). Nuclear segmentation was based on Hoechst channel. Subsequently, cells were recon-185 structed virtually. In the case of tumour cells, the expansion followed the tumour mask 186 stain (Figure 2C). In the case of immune cells, the nuclear circumference was expanded by 187 a specific radius. Whole slide images were analysed with Indica Labs Halo<sup>®</sup> AI software. 188 Like with Tissue Studio, only tumour regions were considered after tumour-stroma seg-189 mentation, and nuclear segmentation was based on Hoechst intensity. After segmentation, 190 Halo<sup>®</sup> AI was fed with hundreds of examples in order to distinguish three nuclear types: 191 tumour, immune and stromal nuclei (Figure 2D). Cell simulation was only performed by 192 expanding nuclear circumference since no tumour mask was used, and tumour cells were 193 recognised from their nuclear morphology. Subsequently, cells were classified accordingly 194 and single/multiple expressions were quantified. 195

Spatial analysis was also performed for whole slides using dHalo<sup>®</sup> software. Four 196 different analyses were performed: Infiltration analysis to determine the density of PD-197  $1^+$  T cells in 5 distance bands within and outside the tumour margin (Figure 3); nearest 198 neighbour analysis to determine the number of PD-1<sup>+</sup> T cells nearby each PD-L1<sup>+</sup> tumour 199 cell within a specific radius; proximity analysis to determine the distance of PD-1<sup>+</sup> T cellos 200 from PD-L1<sup>+</sup> tumour cells, and density heatmap analysis to visualise the density of PD-L1 201 tumour cell density across the tissue section (Figure 4). 202

176

180

Version October 13, 2022 submitted to Cancers



**Figure 2. (A)** TMA core showing nuclear (blue) and tumour (green) stain; **(B)** same TMA core after tumour (orange) stroma (blue) segmentation in Definiens<sup>®</sup> Tissue Studio; **(C)** tumour cell simulation following tumour mask: positive tumour cells are shown in dark yellow, while tumour cells positive for PD-L1 are shown in bright yellow; **(D)** nuclear phenotyping only based on nuclear morphology using Halo<sup>®</sup> AI showing tumour nuclei (green), immune nuclei (purple) and fibroblast nuclei (yellow).

Version October 13, 2022 submitted to Cancers



Figure 3. Schematic representation of distance bands assessed in infiltration analysis. The tumour margin is represented by the yellow line between band 5 and 6. Each band was  $100\mu$ m in thickness. Marker densities were quantified in each band separately as well as in multiple adjacent bands (see figure 1).



Figure 4. (A) Nearest neighbour analysis quantified the number of PD-1<sup>+</sup> T cells nearby each PD-L1<sup>+</sup> tumour cell within a specific radius; (B) Proximity analysis quantified the distance of PD-1<sup>+</sup> T cells from PD-L1<sup>+</sup> tumour cells; (C) Proximity analysis, closer view; (D) Infiltration analysis quantified the density of PD-1<sup>+</sup> T cells in 5 distance bands within and outside the tumour margin; (E) Infiltration analysis, distance bands visualised on the real image; (F) Density heatmap showing PD-L1<sup>+</sup> tumour cells distributed mainly on the tumour margin.

medRxiv preprint doi: https://doi.org/10.1101/2022.10.13.22281035; this version posted October 13, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license

9 of 21

#### 2.6. Statistical analysis

Statistical analysis of 67 and 152 molecular features was performed in TMAs and WSs, 204 respectively, using R Studio (version 1.1.423) and Python (version 3.8). Seven morphological features, including maximum diameter, pN, stage, Fuhrman grade, ISUP grade, classical 206 LS, and ISUP LS were also investigated in both experiments. Unsupervised clustering 207 according to Pearson's correlation was used to investigate relationships between markers. 208 Cox's proportional hazard method was used to predict 5-year and OS, where CRD was 209 considered as the event. OS and CRD data were collected from the Research Tissue Bank 210 of the Royal Infirmary of Edinburgh. We conducted two sets of experiments: one where 211 we took as input the continuous data, and another where each variable was binarised 212 into high and low after determining the optimal cutpoint in relation with outcome, using 213 the maximally selected rank statistics from the R package *maxstat*. Statistical significance 214 was evaluated using the likelihood ratio test and log-rank test to obtain *p*-values for the 215 continuous and categorical models, respectively. We exhaustively fit Cox models for every 216 combination of one, two, and three markers, and applied Chow-Denning correction [30] to 217 the *p*-values in order to account for multiple testing. Due to the vast number of models that 218 needed to be fit (in the order of millions), we ran the computation in parallel on 20 Linux 219 machines for approximately 12 hours using the Jug library [31] to parallelise the code. 220

#### 3. Results (Tissue Microarray)

For each molecular marker, density was calculated by dividing the number of positive cells by the TMA core area. Subsequently, average density of replicates was calculated. 223

#### 3.1. Pearson's correlation

Unsupervised clustering using Pearson's correlation found positive correlation among 225 morphological, DSP-detected, and IF-detected markers, involved in immune response, 226 immune evasion, T cell exhaustion, as well as CSCs and EMT (Figure 5). 227

Among DSP markers, positive correlation was found between CD163 and CD4, CD44, and CD68. CD3 was positively correlated with CD4, CD44, CD68, and CD8. Moreover, 229 CD44 was positively correlated with CD68. CD8 was positively correlated with CD4 and 230 CD68 (Figure 5).

Among IF markers,  $\beta$ -catenin was positively correlated with DSP Histone H3. PD1<sup>+</sup>CD8<sup>+</sup> 232 cells were positively correlated with CD8<sup>+</sup>LAG-3<sup>+</sup> cells and with CD8<sup>+</sup>LAG-3<sup>+</sup>TIM-3<sup>+</sup> cells. 233 Positive correlation was also found between ZEB1 and TIM-3, as well as CD8 and the 234 following markers: PD-1, PD-L1<sup>+</sup> tumour cells, CD163, and LAG-3. Interestingly, positive 235 correlation was also found between CD8<sup>+</sup>LAG-3<sup>+</sup> cells and CD8<sup>+</sup>PD-1<sup>+</sup> cells (Figure 5), 236 indicating that PD-1 may contribute to an exhausted T cell phenotype. 237

#### 3.2. Survival analysis

#### 3.2.1. Univariate Cox regression

Overall, morphological features showed the highest significance. In particular, the LS 240 with the ISUP nuclear grade instead of the Fuhrman grade was the most significant feature, and was associated with poor OS, see Figure 6A) and 5-year survival, see Figure 6B). Similar 242 results were obtained with pN, Fuhrman LS, and ISUP grade. Among molecular markers, OCT4 alone and in combination with ZEB1 was associated with poorer outcome. Moreover, 244 OCT4<sup>+</sup>ZEB1<sup>+</sup> $\beta$ -catenin was associated with 5-year survival. 245

CD8, total tumour cell density, and PD-L1<sup>-</sup> tumour cell density were associated with 246 longer OS and 5 year survival. CD34 density was associated with longer OS, while DSP-247 detected VISTA was associated with longer 5-year survival. 248

#### 3.2.2. Multivariate Cox regression

We exhaustively fit multivariate Cox regression models on every combination of 250 two and three features, in order to find combinations of markers that exhibit statistically 251 significant predictions of patient outcomes. For the TMA cohort with 74 features, we 252

203

221 222

231

238

239

Version October 13, 2022 submitted to Cancers





Figure 5. Heatmap showing positive (red), negative (blue) or no (white) correlation among molecular markers assessed with DSP (black), IF (green), and morphological (purple) features, aggregating the TMA core replicates by mean per patient. Only correlations with p < 0.05 after Chow-Denning correction are shown.



#### (A) Prediction of OS

(B) Prediction of 5-year survival

Figure 6. Volcano plots showing significant categorical univariate Cox regression features after Chow-Denning correction and their correlation with OS (a) and 5-year survival (b). Features with log(HR) > 0 are positively correlated with the event, whereas those with log(HR) < 0 are negatively correlated.

medRxiv preprint doi: https://doi.org/10.1101/2022.10.13.22281035; this version posted October 13, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in percentitiv

perpetuity. It is made available under a CC-BY 4.0 International license .

consequently fit  $\binom{74}{2} + \binom{74}{3} + \binom{74}{4} = 1,218,151$  Cox models. After Chow-Denning correction, we found numerous groups of markers that were predictive for OS or 5-year survival. As expected, most of these groups included features which individually were already statistically significant in the univariate model. However, some groups comprised entirely of markers that were not statistically significant when considering the markers individually in univariate Cox regression, but in combination achieved statistical significance.

In particular, coexpression of CD8 and LAG-3, representing an exhausted T cell pheno-259 type, along with HLA DR, an isotype of the human leukocyte antigens, was identified as a 260 prognostic combination for 5-year survival, suggesting that MHC II plays a crucial role in T 261 cell exhaustion. OCT4 alone or coexpressed with vimentin, reached statistical significance 262 for OS and 5-year survival, respectively, after pairing with Arginase 1 (Arg1), suggesting 263 that CSC and EMT may be linked favouring cancer proliferation. OCT4 combination with 264 HLA DR was also associated with shorter 5-year survival. OCT4<sup>+</sup>vimentin<sup>+</sup> cancer cells 265 also stratified patients by OS when combined with PD-1 expression and snail. Unexpectedly, PD-1<sup>+</sup> cell expression was associated with longer OS when combined with snail<sup>+</sup>vimentin<sup>+</sup> 267 tumour cells, therefore further investigation is needed. When OCT4<sup>+</sup> $\beta$ -catenin<sup>+</sup> cancer cell 268 expression was combined with TIM-3, detected through DSP, it showed shorter OS and 269 5-year survival. Instead, OCT4<sup>+</sup>ZEB1<sup>+</sup> $\beta$ -catenin<sup>+</sup> tumour cell expression showed shorter OS when combined with snail+vimentin+ tumour cell expression. This set of marker groups 271 may provide insight into complex interactions between features that have an impact on predicting patient outcome. Table 2 lists all pairs of markers (i.e. combinations of two) in 273 this category<sup>1</sup>.

As is evident in Figure 6A, Cox regression showed that OCT4<sup>+</sup>ZEB1<sup>+</sup> tumour cells 275 were associated with CRD. However, tumour cells only expressing OCT4 were not found 276 to predict the outcome with statistical significance and neither did the ones only expressing 277 ZEB1. Furthemore, in bivariate Cox regression, OCT4<sup>+</sup> and ZEB1<sup>+</sup> in combination was 278 not a statistically significant predictor of outcome. This means that merely knowing the 279 densities of OCT4<sup>+</sup> cells and ZEB1<sup>+</sup> cells is insufficient; instead, knowledge of the density 280 of cells coexpressing *both* markers is required to arrive at a prediction carrying statistical 281 significance. This highlights the need for accurate and precise spatial analysis that can 282 identify co-registered markers on the same cell. This result also suggests that coexpression 283 of OCT4 and ZEB1 in tumour cells may not only be indicative of a dedifferentiation, but 284 also that CSC and EMT may be dependent mechanisms. 28

#### 3.3. Integrated LS

While the LS is able to stratify patients into low, intermediate and high risk groups, 287 patients at intermediate risk still exhibit varied outcomes. In this section, we evaluate how 288 a combination of the LS with molecular markers can result in better stratification. 289

As baseline, we assessed the stratification ability of the traditional LS on the TMA cohort. After scoring the patients, Kaplan-Meier analysis was able to accurately separate high and intermediate risk groups (p < 0.0001) (Figure 7). Only six patients showed low risk score (0-3), and were therefore excluded from the analysis.

Since traditional LS only relies on morphological data, we tested the stratification ability of the molecular markers that resulted significant in survival analysis. In particular, we found that two specific molecular markers were able to further stratify the patients at intermediate risk according to ISUP LS: IF-detected OCT4<sup>+</sup> tumour cell density was used to stratify patients into intermediate-high and intermediate-low groups (Figure 8A). Eight patients were excluded from this analysis since their OCT4 data were not available. Similarly, CD34, detected through DSP, showed the same stratification ability (Figure 8B).

To further demonstrate the prognostic value of these markers, they were integrated <sup>301</sup> in the LS algorithm. The patients were categorised in high and low risk according to <sup>302</sup>

<sup>&</sup>lt;sup>1</sup> We mention some statistically significant combinations of more than two markers, but do not provide the full list in this paper for the sake of brevity.

Version October 13, 2022 submitted to Cancers

Table 2. Table of pairs of markers that were insignificant in univariate Cox regression individually (p > 0.05), but when used together as input to a multivariate Cox model achieved p < 0.05 after Chow-Denning correction. Markers annotated with  $\uparrow$  exhibit positive correlation with the event, whereas  $\downarrow$  denotes negative correlation.

survival	markers		<i>p</i> -value
5yr	↓ HLA-DR	↓ CD8+LAG3+ T cells	0.011
5yr	↓ ARG1	$\uparrow$ OCT4 <sup>+</sup> tumour cells	0.016
5yr	↓ TIM3	$\uparrow$ OCT4 <sup>+</sup> $\beta$ -catenin <sup>+</sup> tumour cells	0.020
5yr	↓ ARG1	↑ OCT4 <sup>+</sup> vimentin <sup>+</sup> tumour cells	0.027
5yr	$\uparrow$ OCT4 <sup>+</sup> vimentin <sup>+</sup> tumour cells	$\downarrow$ snail <sup>+</sup> vimentin <sup>+</sup> tumour cells	0.030
5yr	↓ HLA-DR	↑ OCT4 <sup>+</sup> vimentin <sup>+</sup> tumour cells	0.038
5yr	$\downarrow$ CD8 <sup>+</sup> TIM3 <sup>+</sup> T cells	↑ TIM3 <sup>+</sup> cells	0.044
overall	$\uparrow$ OCT4 <sup>+</sup> vimentin <sup>+</sup> tumour cells	$\downarrow$ PD-1 <sup>+</sup> cells	0.011
overall	$\uparrow$ OCT4 <sup>+</sup> ZEB1 <sup>+</sup> $\beta$ -catenin <sup>+</sup> tumour	$\downarrow$ snail <sup>+</sup> vimentin <sup>+</sup> tumour cells	0.019
overall	Cells	$\uparrow OCT4^+\beta$ cotonin <sup>+</sup> tumour colls	0.022
overall	$\Rightarrow OCT 4^{+}$ and the $\pm$ because collection	0014 p-catelini tunioui cens	0.022
overall	$\uparrow$ OCT4 vinenum tumour cells	$\downarrow$ shall vimenting tumour cells	0.022
overall	DC14 'vimentin' tumour cells	$\downarrow$ snall tumour cells	0.035
overall	$\downarrow$ PD-1 cells	$\downarrow$ snall 'vimentin' tumour cells	0.037



Figure 7. Kaplan-Meier plot showing patient at high (yellow) and intermediate (blue) risk according to ISUP LS.





Version October 13, 2022 submitted to Cancers







(B) CD34<sup>high</sup>

Figure 9. Kaplan-Meier plots showing stratification of patients with integrated LS using (A) IF OCT4<sup>high</sup> and (B) DSP CD34<sup>high</sup>.

marker expression and LS. Interestingly, OCT4<sup>high</sup> integrated in the ISUP LS was able to 303 significantly stratify patients (Figure 9A). The same result was obtained when CD34<sup>high</sup> 304 was integrated into the algorithm (Figure 9B). 305

## 4. Results (Whole Slides)

## 4.1. Pearson's correlation

Positive correlation was found between CD8<sup>+</sup> immune cells and PD-L1<sup>+</sup> tumour cells, 308 between OCT4a<sup>+</sup> tumour cells and ZEB1<sup>+</sup>SNAIL<sup>+</sup> tumour cells. Interestingly, positive 309 correlation was also found between OCT4a<sup>+</sup> tumour cells and mean tumour cell nuclear 310 area, although no correlation was found with tumour grade. Positive correlation was found 311 between PD1<sup>+</sup>CD8<sup>+</sup> T cells and PD-L1<sup>+</sup> tumour cells. TIM-3<sup>+</sup>PD-L1<sup>+</sup> tumour cells were 312 positively correlated with PD-1<sup>+</sup>CD8<sup>+</sup> T cells.

#### 4.2. Cox regression

Categorical univariate Cox regression showed that ZEB1<sup>+</sup>snail<sup>+</sup> tumour cells and 315 snail<sup>+</sup>CD44<sup>+</sup> tumour cells were associated with longer OS and 5-year survival. Unexpect-316 edly, snail<sup>+</sup>ZEB1<sup>+</sup>CD44<sup>+</sup> tumour cell density was associated with longer 5-year survival 317 (Figure 11). Therefore, further analysis is needed in order to better reveal the role of these 318 markers. 319

Multivariate analysis showed that combination of PD1<sup>+</sup> T cells and ZEB1<sup>+</sup>snail<sup>+</sup> 320 predicted 5-year survival, whereas these two features did not reach statistical significance 321 alone. 322

Survival analysis was performed to predict OS and 5-year survival using the classic 323 ISUP and integrated LSs. The classic LS's stratification ability in the WS cohort is shown in 324 Figure 12. 325

However, stratification of patients at intermediate risk did not show significant results 326 due to the small sample size. 327





Figure 10. Heatmap showing positive (red), negative (blue) or no (white) correlation among morphological (black) and IF (green) markers in the WS cohort after unsupervised clustering. Features including OCT4a and ZEB1 showed the most correlation, while the only negative correlation was found between the Fuhrman LS and ZEB1<sup>+</sup> tumour cells.



#### (A) Prediction of OS

(B) Prediction of 5-year survival

Figure 11. Volcano plots showing significant categorical univariate Cox regression features after Chow-Denning correction and their correlation with (A) OS and (B) and 5-year survival in the WS cohort. Features with log(HR) > 0 are positively correlated with the event, whereas those with log(HR) < 0 are negatively correlated.

Version October 13, 2022 submitted to Cancers

15 of 21

328



Figure 12. Patients belonging to the whole slide cohort stratified at high (yellow) and low (blue) risk according to the ISUP LS.

#### 5. Discussion

Although in recent years systems pathology has made great steps, it still lacks stan-320 dardised methods with high-plex capability, which are necessary to investigate the complex 330 tumour microenvironment. Nanostring GeoMx<sup>®</sup> DSP overcomes this problem by allowing 331 a high-plex, spatially-resolved assessment of FFPE sections while retaining tissue integrity 332 [32]. In our work, this high-throughput method allowed the identification of positive 333 correlations between a large number of markers. In particular, the CSC marker CD44 334 was positively associated with immune markers, such as CD163, indicating a role of M2 335 macrophages in tumour dedifferentiation, or CD3 and CD4, which are indicative of an 336 immune response. These findings support the hypothesis of a crosstalk between CSCs and 337 TAMs, where TAMs exert a trophic function on stem cells while, in turn, CSCs drive M2 338 macrophage polarisation [33]. This mechanism may represent an innovative therapeutic 339 target. 340

Combining GeoMx<sup>®</sup> DSP with mIF is a novel strategy to select specific regions of interest (ROIs) and obtain more precise information about the role that each marker plays 342 in different areas of the tumour. In this study, GeoMx® DSP was performed using TMAs 343 to allow assessment of a greater number of patients and acquire more robust data. In 344 this setting, each ROI corresponded to a single TMA core. This allowed assessment of co-localisation and hence the relationship among markers. In multivariate analysis, 346 OCT4 and ZEB1 co-expression was only significant for prognosis when the two molecules 347 co-expressed in the same cell. When detected separately, the markers (that is, without 348 co-localisation information) and used as two separate input features in a multivariate model 349 did not reach statistical significance. 350

ZEB1 is a transcription factor that promotes epithelial-to-mesenchymal transition 351 (EMT) by downregulating the epithelial marker E-cadherin, therefore facilitating cell motil-352 ity and cancer dissemination [34]. In whole slides, ZEB1 correlated with longer overall 353 survival (OS) when co-expressed in the same cell with snail, and longer 5-year survival 354 when co-expressed with CD44 and snail, suggesting that ZEB1 is not the only determinant 355 of outcome and that other factors may prevent EMT in these patients. By contrast, in TMAs, 356 levels of ZEB1 were associated with shorter OS and 5-year survival when co-expressed 357 with OCT4, consistent with the possibility that OCT4 and ZEB1 both play a role in the 358 acquisition of either a CSC or EMT phenotype [35]. Further investigation is required. 359

The difference between whole slide and TMA may be because whole slide incorporates 360 tumour core and invasive margin, whereas TMA cores were usually sampled from tumour 361 core. ZEB1, snail, CD44, and OCT4 have been reported in the literature to be involved in tumour de-differentiation [36], therefore it is plausible that this mechanism occurs in the 363 tumour core, which is more often hypoxic and hosts stem cell niches [37]. 364 medRxiv preprint doi: https://doi.org/10.1101/2022.10.13.22281035; this version posted October 13, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in pernetuity

perpetuity. It is made available under a CC-BY 4.0 International license .

Version October 13, 2022 submitted to Cancers

16 of 21

We have shown a pipeline of work that can be used to interrogate samples of cancer from patients using several analytical approaches. AI-based image analysis of both mIF 366 and DSP produces an overwhelming amount of data which was possible to analyse only 367 with machine learning-based statistical methods and required computational capability 368 alongside substantial engineering efforts in terms of parallel computing to exhaustively assess all feature combinations. When analysing large volumes of data, the risk of overfitting 370 is proportional to the number of features analysed, and further increases when the number 371 of patients is not large enough [38]. We applied Chow-Denning correction [30] to account 372 for multiple testing, which is slightly less conservative than Bonferroni correction [39]. 373 However, further validation with an external cohort is required to confirm our findings. 374

It is noteworthy that samples were taken before therapy administration, and no therapy 375 information was available in our metadata, so different therapeutic strategies may have 376 been applied to the patients, therefore differently influencing outcome. This is important 377 to consider also due to the large time span between the first and last sample collection, 378 which may also be influenced by the evolution of operative techniques in sample collection. 379 Another aspect to take into account is the deterioration of the FFPE tissue quality, since it 380 has been reported that antigen quality may decay with time especially those expressed in 381 the nucleus or on the cell surface [40]. However, we have conducted many studies using quantitative mIF and this has not appeared to be a problem. Moreover, mRNA extraction 383 from similar old FFPE samples was previously validated [41], while no significant mRNA 384 deterioration was found when FFPE slides at different storage time were compared after 385 DSP analysis [42].

To conclude, both statistical analyses in whole slide and TMA samples found that 387 morphological features on their own were stronger predictors than the molecular ones. An 388 AI-based approach to better profile morphology of ccRCC TME could help standardise 389 prognostic tools and overcome inter-observer bias. However, when molecular markers were 390 integrated in the LS, the accuracy in stratifying patients at intermediate risk significantly 391 improved. Therefore, molecular markers are crucial for identifying differences that are 392 not noticeable by only looking at the tumour morphology. Moreover, adding prognostic 393 immune markers to these scoring algorithms may add important information about ICI 394 response, and may be crucial to apply the appropriate personalised therapy. 395

Author Contributions: Conceptualisation, R.D.F., G.W., D.J.H, P.D.C. and O.A.; methodology, R.D.F,396I.H.U., A.W., G.W., E.S. and E.T.; software, R.D.F. and G.W.; validation, R.D.F. and G.W.; formal397analysis, R.D.F. and G.W.; data curation, R.D.F. and G.W.; writing—original draft preparation, R.D.F.398and G.W.; writing—review and editing, R.D.F., G.W., I.H.U., P.D.C., S.W., A.W., E.S., E.T., O.A.399and D.J.H.; supervision, D.J.H., O.A. and S.W.; project administration, D.J.H. and O.A.; funding400acquisition, D.J.H. and O.A. All authors have read and agreed to the published version of the401manuscript.402

**Funding:** This work was supported by Medical Research Scotland (MRS), NHS Lothian, NanoString Technologies, and the Industrial Centre for AI Research in Digital Diagnostics (iCAIRD) which is funded by Innovate UK on behalf of UK Research and Innovation (UKRI) [project number: 104690].

Institutional Review Board Statement: The work was conducted in accordance with the Declarationof Helsinki and approved by the Ethics Committee of NHS Lothian NRS BioResource, REC-approved407Research Tissue Bank (REC approval ref: 15/ES/0094, 23/04/2018).408

**Data Availability Statement:** Data are currently in the process of being made available, pending ethical approval.

Acknowledgments: We would like to acknowledge Mrs Frances Rae and the SCOTRCC and NHS411Lothian tissue banks for collecting and collating the TMA samples used in this study, Mr John412O'Connor for preparing the whole slide samples, and East of Scotland Research Ethics Service for413granting the ethical approval. Further acknowledgements go to Dr Jason Reeves for helping with the414R software scripts.415

Version October 13, 2022 submitted to Cancers

17 of 21

Gender	Male	Female	NA		
	86 (57%)	60 (40%)	4 (3%)		
<b>Age</b> (vears)	Mean	Min	Max		
5 ( )	64	32	94		
Follow-up					
(months)	Mean	Min	Max		
	60	4	252		
Status at end of FU	Dead	Alive	NA		
0110	102 (68%)	40 (26.6%)	8 (5.3%)		
Concor					
related death	Yes	No	NA		
	75 (50%)	75 (50%)	-		
Metastasis at					
diagnosis	Yes	No	NA		
0	46 (30%)	105 (70%)	-		
Leibovich	II: -h	Testamo a dista	Lenn		
Score risk	High	Intermediate	LOW		
	17 (13.7%)	99 (79.8%)	8 (6.5%)		
Lymph-node	Vac	No	ΝA		
involvement	165	INU	INA		
	25 (16%)	125 (84%)	-		
Stage	1	2	3	4	NA
č	8 (6.5%)	11 (8.9%)	100 (81.5%)	4 (3.2%)	-
ISUP Grade	1	2	3	4	NA
	19 (15.3%)	49 (39.5%)	30 (24.2%)	3 (2.4%)	_

## Table A. Clinical data.

Conflicts of Interest: Raffaele De Filippis was partly funded by Nanostring Technologies for his PhD. 416 Sarah Warren and Andrew White are employed by NanoString Technologies. 417

## Appendix A. Patient information

See Table A.

## **Appendix B. Antibodies**

The antibodies used in the experiments are listed in Tables B1 and B2.

421 422

418

419

Version October 13, 2022 submitted to Cancers

Antibody	Brand (Catalog No)	Species	Dilution	Target
CD163	Cell Marque (MRQ-26)	Mouse	1:3000	M2 TAMs
HIF- $2\alpha$	Abcam (ab8265)	Mouse	1:400	Hypoxia
CD105	Abcam (Ab114052)	Mouse	1:1500	Blood vessels
CD8	Agilent (M7 103)	Mouse	1:200	Cytotoxic T cells
CA9	Novus Biological (NB100-417)	Rabbit	1:100	Tumour cells
Pan-Cadherin	Cell Signaling Technology (4068)	Rabbit	1:100	Tumour cells
$\beta$ -catenin	Cell Signaling Technology (8480S)	Rabbit	1:100	EMT
OCT4a	Cell Signaling Technology (C30A3)	Rabbit	1:800	CSLCs
SNAIL	Cell Signaling Technology (3879)	Rabbit	1:500	EMT
Vimentin	Cell Signaling Technology (5741)	Rabbit	1:200	EMT
ZEB1	Cell Signaling Technology (70512)	Rabbit	1:500	EMT
PD-1	Cell Signaling Technology (86163)	Rabbit	1:500	Immune escape
PD-L1	Cell Signaling Technology (13684)	Rabbit	1:500	Immune escape
TIM-3	Abcam (ab185703)	Rabbit	1:500	T cell exhaustion
LAG-3	Novus Biological (NBP1-97657)	Mouse	1:400	T cell exhaustion
CD44	Cell Signaling Technology (37259)	Rabbit	1:500	CSLCs
ZEB1	Proteintech (21544-1-AP)	Rabbit	1:500	EMT

Table B1. Antibodies used in the IF experiments.

Antibody	Panel	Main expression site
4-1BB	Drug target	Cytotoxic T cells
ARG1	Tumour marker	Tumour cells
b-2-microglobulin	Immune cell profiling	Tumour cells
B7-H3	Drug target	Tumour cells
Bcl-2	Tumour marker	Tumour cells
CD11c	Immune cell profiling	Monocytes/macrophages
CD127	Immune activation status	Memory T cells
CD14	Immune cell typing	Monocytes, myeloid cells
CD163	Immune cell typing	M2 macrophages
CD20	Immune cell profiling	B cells
CD25	Immune activation status	T cells
CD3	Immune cell profiling	T cells
CD34	Immune cell typing	Hematopoietic cells
CD4	Immune cell profiling	T-helper cells
CD40	Immune activation status	B cells/APCs
CD45	Immune cell profiling	Macrophages
CD45RO	Immune cell typing	Memory T cells
CD56	Immune cell profiling	NK cells
CD68	Immune cell profiling	Macrophages
CD8	Immune cell profiling	T cells
CD80	Immune activation status	Myeloid cells
CTLA4	Immune cell profiling	T cells
EpCAM	Tumour marker	Tumour cells
FAP-α	Immune cell typing	fibroblasts
Fibronectin	Immune cell profiling	Fibroblasts
GADPH	Positive control	Housekeeper
GITR	Drug target	T cells
GZMB	Immune cell profiling	Cytotoxic T cells
Histone H3	Positive control	Housekeeper
HLA-DR	Immune cell profiling	APCs
ICOS	Immune activation status	T cells
IDO1	Drug target	Myeloid cells
Ki-67	Tumour marker	Tumour cells
LAG-3	Drug target	T cells
OX40L	Drug target	Myeloid cells, T cells
PanCK	Tumour marker	Tumour cells
PD-1	Immune cell profiling	T cells
PD-L1	Immune cell profiling	APCs, tumour cells
PD-L2	Immune cell profiling	APCs, tumour cells
S6	Positive control	Housekeeper
SMA	Immune cell profiling	Fibroblasts
STING	Drug target	Immune cells
TGFB1	Tumour marker	Immune cells
TIM-3	Drug target	T cells
VISTA	Drug target	Myeloid cells, macrophages

Table B2. Antibodies used in the  $\text{GeoMx}^{\textcircled{\text{B}}}$  DSP experiment.

Version October 13, 2022 submitted to Cancers

20 of 21

Refe	rences	423
1.	Siegel, R.L.; Miller, K.D.; Fuchs, H.E.; Jemal, A. Cancer statistics, 2021. <i>CA: a cancer journal for clinicians</i> <b>2021</b> , <i>71</i> , 7–33.	424
2.	Eggener, S.E.; Yossepowitch, O.; Pettus, J.A.; Snyder, M.E.; Motzer, R.J.; Russo, P. Renal cell carcinoma recurrence after	425
	nephrectomy for localized disease: predicting survival from time of recurrence. Journal of clinical oncology 2006, 24, 3101–3106.	426
3.	Padala, S.A.; Barsouk, A.; Thandra, K.C.; Saginala, K.; Mohammed, A.; Vakiti, A.; Rawla, P.; Barsouk, A. Epidemiology of renal	427
	cell carcinoma. <i>World journal of oncology</i> <b>2020</b> , 11, 79.	428
4.	Wei, W.; Lv, Y.; Gan, Z.; Zhang, Y.; Han, X.; Xu, Z. Identification of key genes involved in the metastasis of clear cell renal cell	429
F	carcinoma. Uncology letters 2019, 17, 4321–4328.	430
5.	word, H.; Cublila, A.L.; Humphrey, P.A.; Reuter, V.E.; Oldright, I.M. The 2016 WHO classification of tumours of the unnary	431
6	Warren A V Harrison D WHO/ISUP classification grading and nathological staging of renal cell carcinoma: standards and	432
0.	controversies World journal of urology 2018 36 1913–1926	433
7.	Bektas, S.; Bahadir, B.; Kandemir, N.O.; Barut, F.; Gul, A.E.; Ozdamar, S.O. Intraobserver and interobserver variability of Fuhrman	435
	and modified Fuhrman grading systems for conventional renal cell carcinoma. The Kaohsiung Journal of Medical Sciences 2009,	436
	25, 596–600.	437
8.	Ren, D.; Hua, Y.; Yu, B.; Ye, X.; He, Z.; Li, C.; Wang, J.; Mo, Y.; Wei, X.; Chen, Y.; et al. Predictive biomarkers and mechanisms	438
	underlying resistance to PD1/PD-L1 blockade cancer immunotherapy. Molecular cancer 2020, 19, 1–19.	439
9.	Giraldo, N.A.; Becht, E.; Vano, Y.; Petitprez, F.; Lacroix, L.; Validire, P.; Sanchez-Salas, R.; Ingels, A.; Oudard, S.; Moatti, A.; et al.	440
	Tumor-infiltrating and peripheral blood T-cell immunophenotypes predict early relapse in localized clear cell renal cell carcinoma.	441
	<i>Clinical Cancer Research</i> <b>2017</b> , 23, 4416–4428.	442
10.	Chen, X.; Wang, H.; et al. Prognostic value of vimentin is associated with immunosuppression in metastatic renal cell carcinoma.	443
11	Frontiers in oncology <b>2020</b> , 10, 1181.	444
11.	Kalluri, K.; Weinberg, K.A.; et al. The basics of epithelial-mesenchymal transition. The Journal of clinical investigation 2009,	445
12	Dongre A: Weinberg R A New insights into the mechanisms of enithelial-mesenchymal transition and implications for cancer	446
12.	Nature reviews Molecular cell biology <b>2019</b> , 20, 69–84.	447
13.	Andreiana, B.C.; Stepan, A.E.; Mărgăritescu, C.; Tăisescu, O.; Osman, A.; Simionescu, C. Snail and E-cadherin immunoexpression	449
	in clear cell renal cell carcinoma. <i>Current Health Sciences Journal</i> <b>2019</b> , 45, 185.	450
14.	Wu, J.; Ru, N.; Zhang, Y.; Li, Y.; Wei, D.; Ren, Z.; Huang, X.; Chen, Z.; Bian, H. HAb18G/CD147 promotes epithelial-mesenchymal	451
	transition through TGF- $\beta$ signaling and is transcriptionally regulated by Slug. <i>Oncogene</i> <b>2011</b> , <i>30</i> , 4410–4427.	452
15.	Zhang, P.; Sun, Y.; Ma, L. ZEB1: at the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance. Cell	453
	<i>cycle</i> <b>2015</b> <i>, 14,</i> 481–487.	454
16.	Liu, C.Y.; Lin, H.H.; Tang, M.J.; Wang, Y.K. Vimentin contributes to epithelial-mesenchymal transition cancer cell mechanics by	455
1 🗖	mediating cytoskeletal organization and focal adhesion maturation. <i>Oncotarget</i> 2015, 6, 15966.	456
17.	O Brien, S.J.; Flechter, C.; Burton, J.; Hallion, J.; Paas, M.; Patel, A.; Patel, A.; Kochet, A.; Scheurlen, K.; Gardner, S.; et al. Long	457
	signaling in colon adoption of cell death discovery 2021, 7, 1, 14	458
18	Kröger C · Afevan A · Mraz I · Faton F N · Reinhardt F · Khodor VI · Thiru P · Bierie B · Ye X · Burge C B · et al. Acquisition	459
10.	of a hybrid E/M state is essential for tumorigenicity of hasal breast cancer cells. <i>Proceedings of the National Academy of Sciences</i>	400
	<b>2019</b> , 116, 7353–7362.	462
19.	Myszczyszyn, A.; Czarnecka, A.M.; Matak, D.; Szymanski, L.; Lian, F.; Kornakiewicz, A.; Bartnik, E.; Kukwa, W.; Kieda, C.;	463
	Szczylik, C. The role of hypoxia and cancer stem cells in renal cell carcinoma pathogenesis. Stem cell reviews and reports 2015,	464
	11, 919–943.	465
20.	Zöller, M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nature Reviews Cancer 2011,	466
	11, 254–267.	467
21.	Li, X.; Ma, X.; Chen, L.; Gu, L.; Zhang, Y.; Zhang, F.; Ouyang, Y.; Gao, Y.; Huang, Q.; Zhang, X. Prognostic value of CD44	468
22	expression in renal cell carcinoma: a systematic review and meta-analysis. <i>Scientific reports</i> <b>2015</b> , <i>5</i> , 1–8.	469
22.	Ma, C.; Komohara, Y.; Ohnishi, K.; Shimoji, I.; Kuwahara, N.; Sakumura, Y.; Matsuishi, K.; Fujiwara, Y.; Motoshima, I.; Takahashi,	470
	W,; et al. Infiltration of tumor-associated macrophages is involved in CD 44 expression in clear cell renai cell carcinoma. Cuncer	471
23	Zhou Y. Chen X. Kang B. She S. Zhang X. Chen C. Li W. Chen W. Dan S. Pan X. et al. Endogenous authentic OCT44	472
23.	proteins directly regulate FOS/AP-1 transcription in somatic cancer cells <i>Cell death &amp; disease</i> <b>2018</b> , 9, 1–16	473
24.	Rasti, A.; Mehrazma, M.; Madid, Z.; Abolhasani, M.; Zaniani, L.S.: Asgari, M. Co-expression of cancer stem cell markers OCT4	475
	and NANOG predicts poor prognosis in renal cell carcinomas. <i>Scientific reports</i> <b>2018</b> , <i>8</i> , 1–11.	476
25.	Waggoner, S.N.; Cornberg, M.; Selin, L.K.; Welsh, R.M. Natural killer cells act as rheostats modulating antiviral T cells. Nature	477
	2012, 481, 394–398.	478
26.	Comber, J.D.; Philip, R. MHC class I antigen presentation and implications for developing a new generation of therapeutic	479
	vaccines. <i>Therapeutic advances in vaccines</i> <b>2014</b> , 2, 77–89.	480

Version October 13, 2022 submitted to Cancers

27.	Caie, P.D.; Dimitriou, N.; Arandjelović, O. Precision medicine in digital pathology via image analysis and machine learning. In	481
	<i>Artificial intelligence and deep learning in pathology;</i> Elsevier, 2021; pp. 149–173.	482
28.	Geiss, G.K.; Bumgarner, R.E.; Birditt, B.; Dahl, T.; Dowidar, N.; Dunaway, D.L.; Fell, H.P.; Ferree, S.; George, R.D.; Grogan, T.; et al.	483
	Direct multiplexed measurement of gene expression with color-coded probe pairs. <i>Nature biotechnology</i> <b>2008</b> , <i>26</i> , 317–325.	484
29.	Merritt, C.R.; Ong, G.T.; Church, S.E.; Barker, K.; Danaher, P.; Geiss, G.; Hoang, M.; Jung, J.; Liang, Y.; McKay-Fleisch, J.; et al.	485
	Multiplex digital spatial profiling of proteins and RNA in fixed tissue. <i>Nature biotechnology</i> <b>2020</b> , <i>38</i> , 586–599.	486
30.	Chow, K.V.; Denning, K.C. A simple multiple variance ratio test. <i>Journal of Econometrics</i> <b>1993</b> , <i>58</i> , 385–401.	487
31.	Coelho, L.P. Jug: Software for parallel reproducible computation in python. <i>Journal of Open Research Software</i> 2017, 5.	488
32.	Beechem, J.M. High-plex spatially resolved RNA and protein detection using digital spatial profiling: a technology designed for	489
	immuno-oncology biomarker discovery and translational research. In Biomarkers for Immunotherapy of Cancer; Springer, 2020; pp.	490
	563–583.	491
33.	Raggi, C.; Mousa, H.; Correnti, M.; Sica, A.; Invernizzi, P. Cancer stem cells and tumor-associated macrophages: a roadmap for	492
	multitargeting strategies. Oncogene 2016, 35, 671–682.	493
34.	Harb, O.A.; Elfeky, M.A.; El Shafaay, B.S.; Taha, H.F.; Osman, G.; Harera, I.S.; Gertallah, L.M.; Abdelmonem, D.M.; Embaby,	494
	A. SPOP, ZEB-1 and E-cadherin expression in clear cell renal cell carcinoma (cc-RCC): Clinicopathological and prognostic	495
	significance. <i>Pathophysiology</i> <b>2018</b> , 25, 335–345.	496
35.	Shao, M.; Bi, T.; Ding, W.; Yu, C.; Jiang, C.; Yang, H.; Sun, X.; Yang, M. OCT4 potentiates radio-resistance and migration activity of	497
	rectal cancer cells by improving epithelial-mesenchymal transition in a ZEB1 dependent manner. <i>BioMed Research International</i>	498
•	<b>2018</b> , 2018.	499
36.	Mani, S.A.; Guo, W.; Liao, M.J.; Eaton, E.N.; Ayyanan, A.; Zhou, A.Y.; Brooks, M.; Reinhard, F.; Zhang, C.C.; Shipitsin, M.; et al.	500
07	The epithelial-mesenchymal transition generates cells with properties of stem cells. <i>Cell</i> <b>2008</b> , <i>133</i> , 704–715.	501
37.	Najafi, M.; Farhood, B.; Mortezaee, K.; Kharazinejad, E.; Majidpoor, J.; Ahadi, K. Hypoxia in solid tumors: a key promoter of	502
20	cancer stem cell (CSC) resistance. Journal of cancer research and clinical oncology 2020, 146, 19–31.	503
38.	Xu, C.; Jackson, S.A. Machine learning and complex biological data, 2019.	504
39.	Bonferroni, C. Teoria statistica delle classi e calcolo delle probabilita. <i>Pubblicazioni del R Istituto Superiore di Scienze Economiche e</i>	505
10	Commerciali al Firenze 1936, 8, 3–62.	506
40.	Grillo, F.; Bruzzone, M.; Pigozzi, S.; Prosapio, S.; Migliora, P.; Flocca, K.; Mastracci, L. Immunonistocnemistry on old archival	507
41	Paramin blocks: is there an expiry date? <i>Journal of Clinical Pathology</i> 2017, 70, 986–995.	508
41.	bueno, K.; Hugnes, E.; Wagner, S.; Gutin, A.S.; Lanchbury, J.S.; Zneng, Y.; Archer, M.A.; Gustarson, C.; Jones, J. I.; Kushton, K.; et al.	509
	Validation of a molecular and pathological model for five-year mortality risk in patients with early stage lung adenocarcinoma.	510
42	Junia of Indiaca Oncology 2013, 10, 07–73.	511
<b>+</b> ∠.	Spatial Profiler Immune Oncology and Technology 2022, 13, 100069	512
	Spatiar i romen. Inimuno Oncology unu recinology 2022, 15, 100009.	513